studies

mNSCLC - L1 - PDL1 positive, durvalumab plus tremelimumab vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 0.85 [0.61; 1.18] 0.85[0.61; 1.18]MYSTIC (DT ; PDL1>25%), 202010%325NAnot evaluable progression or deaths (PFS)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 1.05 [0.72; 1.53] 1.05[0.72; 1.53]MYSTIC (DT ; PDL1>25%), 202010%325NAnot evaluable objective responses (ORR)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 0.87 [0.55; 1.37] 0.87[0.55; 1.37]MYSTIC (DT ; PDL1>25%), 202010%325NAnot evaluable AE (any grade)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 0.43 [0.15; 1.24] 0.43[0.15; 1.24]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable AE (grade 3-4)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 0.86 [0.56; 1.35] 0.86[0.56; 1.35]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable AE leading to death (grade 5)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 3.45 [1.24; 9.59] 3.45[1.24; 9.59]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 1.63 [0.91; 2.93] 1.63[0.91; 2.93]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable SAE (any grade)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 1.93 [1.22; 3.04] 1.93[1.22; 3.04]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable STRAE (any grade)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 1.05 [0.59; 1.87] 1.05[0.59; 1.87]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable TRAE (any grade)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 0.17 [0.09; 0.30] 0.17[0.09; 0.30]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable TRAE (grade 3-4)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 0.36 [0.22; 0.60] 0.36[0.22; 0.60]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable TRAE leading to death (grade 5)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 0.94 [0.06; 15.13] 0.94[0.06; 15.13]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 1.04 [0.54; 2.03] 1.04[0.54; 2.03]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:43 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 171 - treatments: 634,861